Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics Pharmaceutical Investing
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma Pharmaceutical Investing
Sunlenca® Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV Pharmaceutical Investing
First tazarotene lotion treatment for acne vulgaris, ARAZLO , now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans Pharmaceutical Investing
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer Life Science Investing
Gilead Sciences: Tatiana Williams Leads the Way With the Transinclusive Group Pharmaceutical Investing
Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife Loop in Germany Pharmaceutical Investing
LYNPARZA® in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer Life Science Investing
